Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
Start free trial
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
Special Offer: Just $199
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
OTCMKTS:GTBP

GT Biopharma - GTBP Stock Forecast, Price & News

$1.70
-0.13 (-7.10%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.62
▼
$1.83
50-Day Range
$1.53
▼
$2.20
52-Week Range
$1.46
▼
$4.59
Volume
40,038 shs
Average Volume
35,555 shs
Market Capitalization
$55.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

GT Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
576.5% Upside
$11.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.58) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

See Top Rated MarketRank™ Stocks Here
GTBP stock logo

About GT Biopharma (OTCMKTS:GTBP) Stock

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Stock News Headlines

November 22, 2022 | americanbankingnews.com
Research Analysts Issue Forecasts for GT Biopharma, Inc.'s Q4 2023 Earnings (OTCMKTS:GTBP)
November 10, 2022 | benzinga.com
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting
November 10, 2022 | finance.yahoo.com
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 3, 2022 | finance.yahoo.com
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
November 1, 2022 | finance.yahoo.com
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
October 26, 2022 | finance.yahoo.com
Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
October 25, 2022 | finance.yahoo.com
GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST
October 6, 2022 | finance.yahoo.com
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 4, 2022 | finance.yahoo.com
GT Biopharma Announces Adjournment of Special Shareholders Meeting
September 15, 2022 | seekingalpha.com
GTBP GT Biopharma, Inc.
September 14, 2022 | benzinga.com
GT Biopharma Poster Presentation and Mini Oral...
September 12, 2022 | finance.yahoo.com
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies
September 8, 2022 | finance.yahoo.com
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
August 30, 2022 | finance.yahoo.com
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
August 17, 2022 | nasdaq.com
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
August 11, 2022 | finance.yahoo.com
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
July 8, 2022 | finance.yahoo.com
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
June 15, 2022 | barrons.com
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating GT Biopharma, Inc. for Potential Breach of Fiduciary Duty Claims
June 10, 2022 | finance.yahoo.com
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
May 19, 2022 | finance.yahoo.com
Will GT Biopharma (NASDAQ:GTBP) Spend Its Cash Wisely?
May 16, 2022 | finance.yahoo.com
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
May 12, 2022 | finance.yahoo.com
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
April 11, 2022 | finance.yahoo.com
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
March 28, 2022 | finance.yahoo.com
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 | finance.yahoo.com
GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting
See More Headlines
Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Company Calendar

Last Earnings
10/31/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GTBP
Previous Symbol
OTCMKTS:OXISD
CUSIP
N/A
CIK
109657
Web
www.gtbiopharma.com
Phone
(800) 304-9888
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+576.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,010,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-187.49%
Return on Assets
-127.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.15
Quick Ratio
4.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
32,560,000
Free Float
30,572,000
Market Cap
$55.35 million
Optionable
Not Optionable
Beta
0.73

Key Executives

  • Mr. Michael Martin Breen (Age 59)
    Interim CEO & Exec. Chairman
    Comp: $378.02k
  • Dr. Gregory I. Berk M.D. (Age 64)
    Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board
    Comp: $526.39k
  • Dr. Gavin S. Choy MBA
    PharmD, Chief Clinical Devel. Officer
  • Mr. Manu Ohri (Age 67)
    Chief Financial Officer
  • Dr. Jeffrey S. Miller M.D.
    Consulting Chief Scientific Officer & Scientific Advisor
  • Ms. Stacy Herb M.B.A.
    M.P.H., Sr. VP of Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GTBP Stock - Frequently Asked Questions

Should I buy or sell GT Biopharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GTBP shares.
View GTBP analyst ratings or view top-rated stocks.

What is GT Biopharma's stock price forecast for 2023?

2 analysts have issued 12 month price objectives for GT Biopharma's stock. Their GTBP share price forecasts range from $5.00 to $18.00. On average, they predict the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 576.5% from the stock's current price.
View analysts price targets for GTBP or view top-rated stocks among Wall Street analysts.

How have GTBP shares performed in 2022?

GT Biopharma's stock was trading at $3.05 at the start of the year. Since then, GTBP shares have decreased by 44.3% and is now trading at $1.70.
View the best growth stocks for 2022 here.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (OTCMKTS:GTBP) posted its quarterly earnings data on Monday, October, 31st. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.11.

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), American Cannabis (AMMJ) and GW Pharmaceuticals (GWPH).

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

Who are GT Biopharma's major shareholders?

GT Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.14%), State Street Corp (0.32%), Jane Street Group LLC (0.10%) and Virtu Financial LLC (0.08%).
View institutional ownership trends.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $1.70.

How much money does GT Biopharma make?

GT Biopharma (OTCMKTS:GTBP) has a market capitalization of $55.35 million. The company earns $-58,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The official website for the company is www.gtbiopharma.com. The company can be reached via phone at (800) 304-9888 or via email at info@oxis.com.

This page (OTCMKTS:GTBP) was last updated on 11/29/2022 by MarketBeat.com Staff